Compare Incyte Corporation (INCY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MINISO Group Holding Ltd — how do they compare? Incyte Corporation trades at $121.3 (market cap $24.54B), while MINISO Group Holding Ltd trades at $11.89 (market cap $3.62B). The key difference: Incyte Corporation is far larger — about 6.8× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MNSO | |
|---|---|---|
Market Cap | $24.54B | $3.62B |
Sector | Health | Technology |
52-Week High | $129.93 | $26.63 |
52-Week Low | $81.61 | $11.30 |
Enterprise Value | $20.04B | $4.29B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
MNSO trades at $11.9, down 4.95% in the last session, with a neutral technical signal and bearish moving averages. Recent earnings showed a Q1 2026 beat but prior misses, while fundamentals include a P/E of 12.16 and net margin of 8.98%. The company announced a $2 billion share repurchase in June 2026, supporting sentiment amid mixed performance.
Outlook is cautiously optimistic with 75% analyst buy ratings, but risks include margin pressure from SG&A costs and competitive retail markets. The stock offers value if earnings growth sustains, though volatility from recent declines warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
